Revenue has plummeted to a negligible $2,000 in 2026Q1, reflecting a 71.4% year-over-year contraction and an extreme operating margin deficit of -23,078.5%.
| Sales/Revenue | 31K | 36K | 61K | 130K | 84.68M | 10.65M | 7.76M | 657K |
| Revenue Growth % | -52.31% | -40.98% | -53.08% | -99.85% | 695.15% | 37.31% | 1080.52% | - |
| Cost of Goods Sold | 2.33M | 11.54M | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | 32052.78% | - | - | - | - | - | - |
| Gross Profit | -2.3M | -11.5M | 61K | 130K | 84.68M | 10.65M | 7.76M | 657K |
| Gross Margin % | -7422.58% | -31952.78% | 100% | 100% | 100% | 100% | 100% | 100% |
| Gross Profit Growth % | - | -18957.38% | -53.08% | -99.85% | 695.15% | 37.31% | 1080.52% | - |
| Operating Expenses | 189.56M | 192.27M | 358.82M | 247.14M | 271.74M | 225.43M | 219.69M | 102.75M |
| OpEx % of Revenue | - | 534086.11% | 588222.95% | 190106.15% | 320.89% | 2116.68% | 2832.56% | 15638.66% |
| Selling, General & Admin | 40.64M | 45.13M | 52.04M | 66.98M | 117.31M | 89.06M | 46.88M | 39.15M |
| SG&A % of Revenue | - | 125375% | 85313.11% | 51525.38% | 138.52% | 836.22% | 604.45% | 5959.06% |
| Research & Development | 151.83M | 158.68M | 171.6M | 182.94M | 159.19M | 138.69M | 182.24M | 63.59M |
| R&D % of Revenue | - | 440763.89% | 281316.39% | 140726.92% | 187.98% | 1302.28% | 2349.7% | 9679.6% |
| Other Operating Expenses | -2M | -11.54M | 135.17M | -2.79M | -4.75M | -2.32M | -9.43M | 0 |
| Operating Income | -191.86M | -203.77M | -358.75M | -247.01M | -187.06M | -214.78M | -211.94M | -102.09M |
| Operating Margin % | -618909.68% | -566038.89% | -588122.95% | -190006.15% | -220.89% | -2016.68% | -2732.56% | -15538.66% |
| Operating Income Growth % | - | 43.2% | -45.24% | -32.05% | 12.91% | -1.34% | -107.6% | - |
| EBITDA | -181.43M | -192.24M | -339.12M | -226.76M | -169.04M | -201.15M | -207.64M | -100.83M |
| EBITDA Margin % | -585264.52% | -533986.11% | -555940.98% | -174429.23% | -199.61% | -1888.75% | -2677.19% | -15347.49% |
| EBITDA Growth % | 47.03% | 43.31% | -49.55% | -34.15% | 15.96% | 3.13% | -105.93% | - |
| D&A (Non-Cash Add-back) | 10.43M | 11.54M | 19.63M | 20.25M | 18.02M | 13.62M | 4.29M | 1.26M |
| EBIT | -192.01M | -203.77M | -220.27M | -247.01M | -187.06M | -214.78M | -219.72M | -102.09M |
| Net Interest Income | 11.41M | 13.08M | 24.07M | 23.45M | 7.05M | 1.17M | 5.94M | 8.12M |
| Interest Income | 11.41M | 13.08M | 24.07M | 23.45M | 7.05M | 1.17M | 5.94M | 8.12M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -54.54M | -70.67M | 15.76M | 12.38M | 3.94M | -35.44M | 7.46M | -27.29M |
| Pretax Income | -246.41M | -274.45M | -342.99M | -234.63M | -183.12M | -250.22M | -204.47M | -129.38M |
| Pretax Margin % | -794858.06% | -762355.56% | -562285.25% | -180486.15% | -216.24% | -2349.47% | -2636.31% | -19692.09% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -246.41M | -274.45M | -342.99M | -234.63M | -183.12M | -250.22M | -204.47M | -129.38M |
| Net Margin % | -794858.06% | -762355.56% | -562285.25% | -180486.15% | -216.24% | -2349.47% | -2636.31% | -19692.09% |
| Net Income Growth % | 26.34% | 19.98% | -46.18% | -28.13% | 26.82% | -22.37% | -58.04% | - |
| Net Income (Continuing) | -246.41M | -274.45M | -342.99M | -234.63M | -183.12M | -250.22M | -204.47M | -129.38M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -11.26 | -16.06 | -1.31 | -0.93 | -0.74 | -1.03 | -0.84 | -0.53 |
| EPS Growth % | -919.69% | -1125.95% | -40.14% | -26.14% | 28.1% | -22.16% | -59.42% | - |
| EPS (Basic) | - | -16.06 | -1.31 | -0.93 | -0.74 | -1.03 | -0.84 | -0.53 |
| Diluted Shares Outstanding | 21.88M | 17.09M | 13.07M | 12.55M | 12.35M | 12.14M | 12.33M | 12.33M |
| Basic Shares Outstanding | 21.88M | 17.09M | 13.07M | 12.55M | 12.35M | 12.14M | 12.33M | 12.33M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
Clinical trial funding shortfall
As reported in recent financial filings, Lyell Immunopharma's revenue has plummeted to a negligible $2,000 in 2026Q1, reflecting a 71.4% year-over-year decline that underscores the company's total reliance on non-recurring, project-based collaboration inflows rather than any sustainable commercial product sales or recurring service revenue streams.
The consistent contraction in top-line figures suggests that the initial partnership-driven revenue model has largely exhausted its accounting recognition phase. Investors should interpret this trend as a clear signal that the firm remains in a pre-revenue, purely experimental stage where top-line growth is essentially irrelevant to valuation.
Based on the company's reported income statements, research and development expenses remain the primary driver of cash outflows, consistently consuming tens of millions per quarter despite the absence of meaningful revenue to offset the high costs of specialized cell reprogramming and clinical trial infrastructure maintenance.
The persistent R&D spend, which reached $36.6 million in the most recent quarter, indicates a high-burn operational model that is heavily sensitive to clinical trial timelines. This cost structure appears rigid, suggesting that management has limited flexibility to reduce expenses without compromising the core development of the LYL797 and LYL845 programs.
According to historical income statement data, Lyell Immunopharma exhibits extreme operating margin deficits, with the most recent quarter showing an operating margin of -23,078.5%, illustrating a complete lack of operating leverage as the company continues to scale its clinical infrastructure without any corresponding commercial revenue generation.
The massive disparity between operating expenses and revenue suggests that the company is currently in a phase of maximum capital intensity. This indicates that any future path to profitability is entirely dependent on successful clinical readouts rather than operational efficiencies or economies of scale within the current business model.
As indicated by the provided financial statements, the company's net income is consistently negative, with stock-based compensation periodically adding significant non-cash expenses that further distort the underlying cash burn profile and complicate the assessment of true operational efficiency for the early-stage biotechnology entity.
The volatility in net income, often driven by non-operating items and accounting adjustments, warrants caution for analysts attempting to model future performance. Investors should focus on the net cash burn rate rather than reported EPS, as the latter is currently a mathematical artifact of a pre-revenue clinical development cycle.
Based on the reported cash position of approximately $60 million, the company faces a precarious financial outlook, as the current rate of quarterly operating losses suggests a rapidly narrowing runway that may force dilutive financing or strategic program prioritization in the near term to ensure survival.
Short-sellers would likely focus on the mismatch between the company's high-burn R&D requirements and its dwindling liquidity. This dynamic suggests that the firm is highly vulnerable to market volatility, as any delay in clinical milestones could necessitate capital raises at potentially unfavorable valuations.
Quick answers to the most common questions about buying LYEL stock.
For fiscal year 2025, Lyell Immunopharma, Inc. (LYEL) reported total revenue of $0.0M. This represents a 94.5% decline compared to $0.7M in 2019.
Lyell Immunopharma, Inc. (LYEL) reported a net loss of $274.4M for the fiscal year ending 2025.
Lyell Immunopharma, Inc. (LYEL) reported an operating income of $-203.8M, resulting in an operating profit margin of -566038.9%. This margin reflects the operational efficiency of the business before interest and taxes.
Lyell Immunopharma, Inc. (LYEL) generated $-11.5M in gross profit for the year, representing a gross profit margin of -31952.8%. This demonstrates the company's core pricing power and production efficiency.